Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.03 and traded as high as $2.98. Spero Therapeutics shares last traded at $2.94, with a volume of 1,836,464 shares.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded shares of Spero Therapeutics to a "hold" rating in a report on Saturday. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $5.00.
Read Our Latest Analysis on SPRO
Spero Therapeutics Price Performance
The company has a market capitalization of $168.85 million, a P/E ratio of -2.36 and a beta of 1.31. The company has a 50 day moving average of $1.41 and a 200-day moving average of $1.05.
Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.30. The business had revenue of $5.87 million during the quarter, compared to analyst estimates of $11.00 million. Spero Therapeutics had a negative return on equity of 123.50% and a negative net margin of 156.48%. Research analysts predict that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.
Institutional Trading of Spero Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Monimus Capital Management LP bought a new position in Spero Therapeutics in the 4th quarter worth $320,000. Virtu Financial LLC purchased a new position in shares of Spero Therapeutics during the fourth quarter valued at about $47,000. Prudential Financial Inc. bought a new position in Spero Therapeutics in the fourth quarter worth about $51,000. JPMorgan Chase & Co. raised its stake in Spero Therapeutics by 26,011.9% in the fourth quarter. JPMorgan Chase & Co. now owns 61,624 shares of the company's stock worth $63,000 after buying an additional 61,388 shares in the last quarter. Finally, ADAR1 Capital Management LLC lifted its holdings in Spero Therapeutics by 7.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 801,277 shares of the company's stock worth $825,000 after buying an additional 57,818 shares during the period. Hedge funds and other institutional investors own 25.60% of the company's stock.
About Spero Therapeutics
(
Get Free Report)
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Further Reading
Before you consider Spero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spero Therapeutics wasn't on the list.
While Spero Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
